Rankings
▼
Calendar
TCRX Q4 2020 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TCRX
TScan Therapeutics, Inc.
$65M
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$795,000
Gross Profit
-$5M
-650.2% margin
Operating Income
-$8M
-982.4% margin
Net Income
-$8M
-982.0% margin
EPS (Diluted)
$-0.33
QoQ Revenue Growth
+174.1%
Cash Flow
Operating Cash Flow
-$7M
Free Cash Flow
-$9M
Stock-Based Comp.
$150,000
Balance Sheet
Total Assets
$50M
Total Liabilities
$92M
Stockholders' Equity
-$42M
Cash & Equivalents
$35M
← FY 2020
All Quarters
Q1 2021 →